Photo: Dr. Jennifer Kuo. Courtesy of Trinity Health Community News Dr. Jennifer Kuo, a urologist with Trinity Health IHA ...

Francis Medical has obtained $80 million in venture capital funding to support the development of its water vapor ablation ...

The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.

Francis Medical announced today that it has completed an oversubscribed $80 million Series C equity financing.

Dec. 10, 2024 — In a single IV injection, a gene therapy targeting cBIN1 can reverse the effects of heart failure and restore heart function in a large animal model. The therapy increases the ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

While cryotherapy can be effective, it’s not the right treatment for everybody so it’s good for you to know what it entails.

Medical experts emphasize that regular prostate screenings, particularly through rectal examinations, remain one of the most ...

As temperatures drop, a trend of increased prostate-related problems among men over 60 has been observed by experts. Benign prostatic hyperplasia (BPH), also called prostate gland enlargement, is a ...

Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...

Bladder cancer is a cancer that forms in tissues ... invasive and metastatic urothelial cancers (MIBC/mUC) for targeted therapy remains challenging, but clinically important.

Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) s ...